ATE419391T1 - Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen - Google Patents

Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen

Info

Publication number
ATE419391T1
ATE419391T1 AT03799104T AT03799104T ATE419391T1 AT E419391 T1 ATE419391 T1 AT E419391T1 AT 03799104 T AT03799104 T AT 03799104T AT 03799104 T AT03799104 T AT 03799104T AT E419391 T1 ATE419391 T1 AT E419391T1
Authority
AT
Austria
Prior art keywords
pancreatic cancer
pnc
genes
human pancreatic
pancreatic carcinoma
Prior art date
Application number
AT03799104T
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE419391T1 publication Critical patent/ATE419391T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03799104T 2002-09-30 2003-09-12 Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen ATE419391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41487202P 2002-09-30 2002-09-30
US45088903P 2003-02-28 2003-02-28

Publications (1)

Publication Number Publication Date
ATE419391T1 true ATE419391T1 (de) 2009-01-15

Family

ID=32073343

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03799104T ATE419391T1 (de) 2002-09-30 2003-09-12 Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
AT03799106T ATE419390T1 (de) 2002-09-30 2003-09-17 Verfahren zur diagnose von bauchspeicheldrüsenkrebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03799106T ATE419390T1 (de) 2002-09-30 2003-09-17 Verfahren zur diagnose von bauchspeicheldrüsenkrebs

Country Status (10)

Country Link
US (3) US7601826B2 (de)
EP (3) EP1556518B1 (de)
JP (2) JP4679149B2 (de)
CN (1) CN1703524B (de)
AT (2) ATE419391T1 (de)
AU (2) AU2003260966A1 (de)
CA (2) CA2500472A1 (de)
DE (2) DE60325628D1 (de)
ES (1) ES2320443T3 (de)
WO (2) WO2004031411A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
EP1730279A2 (de) * 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 als therapeutisches ziel von prc und pdaca
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
WO2005116259A2 (en) 2004-05-21 2005-12-08 The Board Of Trustees Of The University Of Arkansas System Use of gene expression profiling to predict survival in cancer patient
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006038904A2 (en) * 2004-08-06 2006-04-13 Applera Corporation Method and compositions for treating diseases targeting e-cadherin
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE102004049897B4 (de) * 2004-10-13 2007-11-22 Sirs-Lab Gmbh Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
EP1917274A2 (de) * 2005-07-28 2008-05-07 Oncotherapy Science, Inc. Vivit-polypeptide, therapeutisches mittel, das diese enthält, und verfahren zum screening auf antikrebsmittel
WO2007035676A2 (en) * 2005-09-19 2007-03-29 Veridex., Llc Methods and materials for identifying the origin of a carcinoma of unknown primary origin
CN101415440A (zh) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 治疗肺癌的方法
EP2004228A1 (de) 2006-02-28 2008-12-24 Oncotherapy Science, Inc. Verfahren zur schädigung von zellen mit effektor-funktionen von anti-epha4-antikörpern
US20090155799A1 (en) * 2006-03-02 2009-06-18 Yusuke Nakamura Methods for diagnosing pancreatic cancer using reg4 protein
CN1904072B (zh) * 2006-07-28 2012-07-18 浙江大学 一组筛选胰腺导管腺癌的基因组合及应用
WO2008020596A2 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Treating or preventing cancers over-expressing reg4 or kiaa0101
US7811778B2 (en) * 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
CN101680896A (zh) 2007-03-27 2010-03-24 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
AU2008290049B2 (en) 2007-08-20 2013-08-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
MX2010002018A (es) 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
EP2313504B1 (de) 2008-06-30 2015-01-07 Oncotherapy Science, Inc. Radioisotopmarkierte anti-cdh3-antikörper und verwendungen davon
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
RU2011111387A (ru) * 2008-08-27 2012-10-10 Онкотерапи Сайенс, Инк. (Jp) Syngr4 в качестве генов-мишеней для терапии и диагностики рака
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
TW201023893A (en) * 2008-11-17 2010-07-01 Bioalliance Cv Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
DE102010043541B4 (de) * 2009-12-16 2012-01-26 Technische Universität Dresden Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
JP2013518560A (ja) * 2010-02-03 2013-05-23 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｗｈｓｃ１およびｗｈｓｃ１ｌ１
KR101894111B1 (ko) * 2010-06-01 2018-08-31 메타노믹스 헬스 게엠베하 대상체에서 췌장암을 진단하기 위한 수단 및 방법
EP2591357A4 (de) 2010-07-09 2014-01-01 Somalogic Inc Biomarker für lungenkrebs und verwendung
CA2804857C (en) * 2010-08-13 2021-07-06 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
KR101297336B1 (ko) 2011-03-30 2013-08-14 인하대학교 산학협력단 점액성 낭성종양 진단 장치
KR101223598B1 (ko) 2011-04-06 2013-01-22 인하대학교 산학협력단 췌장 상피내 종양 진단 시스템
CN104011543B (zh) * 2011-10-24 2016-06-15 通用医疗公司 癌症的生物标记
EP2999796B1 (de) 2013-05-20 2017-10-25 BioVentures, LLC Gep5-modell für multiples myelom
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
KR20160132067A (ko) * 2014-03-11 2016-11-16 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 공격성, 예후 및 치료에 대한 반응성의 결정
US10669588B2 (en) 2014-09-26 2020-06-02 Hi-Stem Ggmbh Methods for sub-typing and treating cancer
GB201501930D0 (en) * 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
CN105017403B (zh) * 2015-07-09 2018-07-03 陈勇 胰腺癌相关多肽dap44单克隆抗体的制备及其应用
EP4219525A3 (de) 2015-10-08 2023-09-27 OncoTherapy Science, Inc. Von foxm1 abgeleitetes peptid und impfstoff damit
JP7320840B2 (ja) * 2017-09-11 2023-08-04 国立大学法人北海道大学 癌治療薬
EP3508855A1 (de) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Verfahren zur auswahl von patienten und kit
KR102328654B1 (ko) * 2019-04-17 2021-11-19 한국원자력의학원 암의 예방 또는 치료용 약학 조성물
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN115074365B (zh) * 2022-06-28 2023-02-28 中国医学科学院北京协和医院 靶向GATM基因的sgRNA及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6333152B1 (en) 1997-05-21 2001-12-25 The Johnshopkins University Gene expression profiles in normal and cancer cells
WO1999031274A2 (en) 1997-12-15 1999-06-24 Abbott Laboratories Reagents and methods useful for detecting diseases of the pancreas
US6262249B1 (en) 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001009317A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Gene associe au cancer de l'estomac
EP1690872A3 (de) 1999-12-01 2006-08-23 Genentech, Inc. Zusammensetzung und Verfahren zur Diagnose eines Tumors
CA2392757A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
EP1504099A4 (de) 2001-12-10 2006-05-10 Nuvelo Inc Neue nukleinsäuren und polypeptide
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CA2500982A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20090155799A1 (en) * 2006-03-02 2009-06-18 Yusuke Nakamura Methods for diagnosing pancreatic cancer using reg4 protein

Also Published As

Publication number Publication date
EP2009117A2 (de) 2008-12-31
EP1549771B1 (de) 2008-12-31
EP2009117A3 (de) 2009-03-18
US7943730B2 (en) 2011-05-17
AU2003260966A1 (en) 2004-04-23
US20120028262A1 (en) 2012-02-02
JP2006500947A (ja) 2006-01-12
DE60325617D1 (de) 2009-02-12
EP1549771A2 (de) 2005-07-06
CA2500482A1 (en) 2004-04-15
AU2003263603A8 (en) 2004-04-23
AU2003260966A8 (en) 2004-04-23
CN1703524B (zh) 2010-04-07
ATE419390T1 (de) 2009-01-15
WO2004031411A3 (en) 2004-09-30
EP1556518B1 (de) 2008-12-31
WO2004031411A2 (en) 2004-04-15
AU2003263603A1 (en) 2004-04-23
CA2500472A1 (en) 2004-04-15
US20100093629A1 (en) 2010-04-15
WO2004031412A3 (en) 2004-07-15
JP2006500948A (ja) 2006-01-12
US7601826B2 (en) 2009-10-13
CN1703524A (zh) 2005-11-30
US20060270619A1 (en) 2006-11-30
ES2320443T3 (es) 2009-05-22
WO2004031412A2 (en) 2004-04-15
JP4679149B2 (ja) 2011-04-27
DE60325628D1 (de) 2009-02-12
EP1556518A2 (de) 2005-07-27

Similar Documents

Publication Publication Date Title
ATE419391T1 (de) Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
DE602004032556D1 (de)
WO2006085684A3 (en) Method of diagnosing bladder cancer
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
IL164757A0 (en) Method for analyzing an alpha-galactosidase a preparation
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
WO2004021010A3 (en) Method of diagnosing colon and gastric cancers
WO2004031414A3 (en) Method for diagnosing prostate cancer
EP1565582A4 (de) Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
DK1694697T3 (da) Overfladelokaliserede Campylobacter jejuni-polypeptider
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
WO2004039312A3 (en) Optineurin and glaucoma
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
WO2007013359A3 (en) Cancer related gene rasgef1a
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
Orhan et al. Peer-reviewede publikationer Klinisk Onkologisk Afdeling, SUH Juli 2024 (n= 26)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties